Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Identifieur interne : 002D53 ( Main/Exploration ); précédent : 002D52; suivant : 002D54Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Auteurs : RBID : pubmed:15864584English descriptors
- KwdEn :
- Animals, Antibodies (blood), Antibodies (immunology), Antibodies (therapeutic use), Avidin (administration & dosage), Carcinoembryonic Antigen (blood), Carcinoembryonic Antigen (therapeutic use), Carcinoma (metabolism), Carcinoma (radiotherapy), Cell Line, Tumor, Colonic Neoplasms (metabolism), Colonic Neoplasms (radiotherapy), Drug Combinations, Drug Delivery Systems (methods), Female, Humans, Iodine Radioisotopes (pharmacokinetics), Iodine Radioisotopes (therapeutic use), Metabolic Clearance Rate (drug effects), Mice, Mice, Nude, Neoplasms, Experimental, Organ Specificity (drug effects), Radioimmunotherapy (methods), Tissue Distribution (drug effects).
- MESH :
- chemical , administration & dosage : Avidin.
- chemical , blood : Antibodies, Carcinoembryonic Antigen.
- chemical , immunology : Antibodies.
- chemical , pharmacokinetics : Iodine Radioisotopes.
- chemical , therapeutic use : Antibodies, Carcinoembryonic Antigen, Iodine Radioisotopes.
- drug effects : Metabolic Clearance Rate, Organ Specificity, Tissue Distribution.
- metabolism : Carcinoma, Colonic Neoplasms.
- methods : Drug Delivery Systems, Radioimmunotherapy.
- radiotherapy : Carcinoma, Colonic Neoplasms.
- Animals, Cell Line, Tumor, Drug Combinations, Female, Humans, Mice, Mice, Nude, Neoplasms, Experimental.
Abstract
Pretargeted therapy with radiolabelled bivalent haptens and bispecific antibodies has shown promising results, but blood clearance of the activity-carrying haptens under conditions designed for radioimmunotherapy is relatively slow. Thus, the chase of excess circulating bispecific antibody by biotinylation of the bispecific antibody and injection of avidin before hapten administration was tested with a view to increasing tumour-to-blood activity ratios.
DOI: 10.1007/s00259-005-1811-2
PubMed: 15864584
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.</title><author><name sortKey="Mirallie, Eric" uniqKey="Mirallie E">Eric Mirallié</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Research Department, Inserm U601, Institut de Biologie, Université de Nantes, 9 quai Moncousu, 44093, Nantes Cedex 1, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cancer Research Department, Inserm U601, Institut de Biologie, Université de Nantes, 9 quai Moncousu, 44093, Nantes Cedex 1</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Sai Maurel, Catherine" uniqKey="Sai Maurel C">Catherine Saï-Maurel</name></author><author><name sortKey="Faivre Chauvet, Alain" uniqKey="Faivre Chauvet A">Alain Faivre-Chauvet</name></author><author><name sortKey="Regenet, Nicolas" uniqKey="Regenet N">Nicolas Regenet</name></author><author><name sortKey="Chang, Chien Hsing" uniqKey="Chang C">Chien-Hsing Chang</name></author><author><name sortKey="Goldenberg, David M" uniqKey="Goldenberg D">David M Goldenberg</name></author><author><name sortKey="Chatal, Jean Francois" uniqKey="Chatal J">Jean-François Chatal</name></author><author><name sortKey="Barbet, Jacques" uniqKey="Barbet J">Jacques Barbet</name></author><author><name sortKey="Thedrez, Philippe" uniqKey="Thedrez P">Philippe Thedrez</name></author></titleStmt><publicationStmt><date when="2005">2005</date><idno type="doi">10.1007/s00259-005-1811-2</idno><idno type="RBID">pubmed:15864584</idno><idno type="pmid">15864584</idno><idno type="wicri:Area/Main/Corpus">002F13</idno><idno type="wicri:Area/Main/Curation">002F13</idno><idno type="wicri:Area/Main/Exploration">002D53</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies (blood)</term><term>Antibodies (immunology)</term><term>Antibodies (therapeutic use)</term><term>Avidin (administration & dosage)</term><term>Carcinoembryonic Antigen (blood)</term><term>Carcinoembryonic Antigen (therapeutic use)</term><term>Carcinoma (metabolism)</term><term>Carcinoma (radiotherapy)</term><term>Cell Line, Tumor</term><term>Colonic Neoplasms (metabolism)</term><term>Colonic Neoplasms (radiotherapy)</term><term>Drug Combinations</term><term>Drug Delivery Systems (methods)</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes (pharmacokinetics)</term><term>Iodine Radioisotopes (therapeutic use)</term><term>Metabolic Clearance Rate (drug effects)</term><term>Mice</term><term>Mice, Nude</term><term>Neoplasms, Experimental</term><term>Organ Specificity (drug effects)</term><term>Radioimmunotherapy (methods)</term><term>Tissue Distribution (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Avidin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies</term><term>Carcinoembryonic Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies</term><term>Carcinoembryonic Antigen</term><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Metabolic Clearance Rate</term><term>Organ Specificity</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma</term><term>Colonic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Carcinoma</term><term>Colonic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Mice</term><term>Mice, Nude</term><term>Neoplasms, Experimental</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pretargeted therapy with radiolabelled bivalent haptens and bispecific antibodies has shown promising results, but blood clearance of the activity-carrying haptens under conditions designed for radioimmunotherapy is relatively slow. Thus, the chase of excess circulating bispecific antibody by biotinylation of the bispecific antibody and injection of avidin before hapten administration was tested with a view to increasing tumour-to-blood activity ratios.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15864584</PMID><DateCreated><Year>2005</Year><Month>08</Month><Day>31</Day></DateCreated><DateCompleted><Year>2005</Year><Month>12</Month><Day>30</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1619-7070</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur. J. Nucl. Med. Mol. Imaging</ISOAbbreviation></Journal><ArticleTitle>Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.</ArticleTitle><Pagination><MedlinePgn>901-9</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Pretargeted therapy with radiolabelled bivalent haptens and bispecific antibodies has shown promising results, but blood clearance of the activity-carrying haptens under conditions designed for radioimmunotherapy is relatively slow. Thus, the chase of excess circulating bispecific antibody by biotinylation of the bispecific antibody and injection of avidin before hapten administration was tested with a view to increasing tumour-to-blood activity ratios.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The anti-carcinoembryonic antigen (CEA) x anti-diethylene triamine penta-acetic acid-indium (di-DTPA-indium) bispecific antibody (hMN-14x734) was derivatised with NHS-LC-biotin and injected into LS-174T tumour-bearing nude mice at a dose of 3.5 nmol, followed by avidin and finally by the 125I-labelled di-DTPA-indium hapten (1 nmol). Blood samples were collected, animals sacrificed and tumours and normal tissues counted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Avidin chased up to 72% of the circulating antibody in the liver and the spleen within 30 min. When the labelled hapten was injected 3 h after avidin, tumour to blood ratios measured 3 and 24 h after hapten injection were significantly improved by the chase (3.5-fold), whereas tumour uptake was not significantly reduced. Uptake in normal tissues was unchanged (liver, kidney) or decreased (muscle), with the exception of spleen, in which uptake of both antibody and hapten was increased by the avidin chase.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The chase strategy reduces hapten concentration in blood and thus should reduce bone marrow exposure. The use of two different recognition systems limits possible interference between the chase and targeting steps.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirallié</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Affiliation>Cancer Research Department, Inserm U601, Institut de Biologie, Université de Nantes, 9 quai Moncousu, 44093, Nantes Cedex 1, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Saï-Maurel</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Faivre-Chauvet</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Regenet</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chien-Hsing</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Thedrez</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>1405-69-2</RegistryNumber><NameOfSubstance>Avidin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies</DescriptorName><QualifierName MajorTopicYN="Y">blood</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Avidin</DescriptorName><QualifierName MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="Y">blood</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Colonic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName><QualifierName MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2005</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-005-1811-2</ArticleId><ArticleId IdType="pubmed">15864584</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15864584
|texte= Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15864584" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |